1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Identifai Fpo [id1]

Identifai Fpo [id1]

ID1.AX
Identifai Fpo [id1]AU flagAustralian Securities Exchange
0.50
AUD
+0.07
- -
95.03MMarket Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

Company Profile APIChatGPT
CEO
Eyal Miller
Sector
Healthcare
Industry
Biotechnology
Address
295 Rokeby Road Subiaco WA Australia 6008
IPO Date
Oct 8, 2026
Website
identifai-genetics.com
Similar Companies
Abivax S.A. (0RA9.L)
Alpha Cognition Inc (ACOG)
AnaptysBio, Inc. (ANAB)
Flerie AB (publ) (FLERIE.ST)
XORTX Therapeutics Inc. (XRTX.V)
Sprint Bioscience AB (SPRINT.ST)
Business
Identifai Genetics Limited provides prenatal genetic screening through the application of genome-wide sequencing and artificial intelligence in Israel, the United States, Hong Kong, China, and Australia. The company's product, Windrose, is a first-trimester non-invasive prenatal test that provides cfDNA-based fetal risk assessment for more than 280 clinically actionable genes, all from a single blood draw and without requiring a partner sample. The company was founded in 2021 and is based in Subiaco, Australia.